[Tempus Second Quarter 2025 Earnings Release](index=1&type=section&id=Tempus%20Reports%20Second%20Quarter%202025%20Results) [Second Quarter 2025 Highlights](index=1&type=section&id=Second%20Quarter%20Summary%20Results) Tempus reported strong Q2 2025 performance with 89.6% revenue growth, a 30% increase in clinical volumes, and significantly narrowed net and Adjusted EBITDA losses - CEO Eric Lefkofsky highlighted that revenues and margins are growing faster than expected, with a significant re-acceleration of clinical volumes, which grew **30% in the quarter**, delivering over **212,000 NGS tests**[3](index=3&type=chunk) - **Genomics revenue grew 115.3% YoY** to $241.8 million, while **Data and services revenue increased 35.7% YoY** to $72.8 million[6](index=6&type=chunk)[7](index=7&type=chunk) Q2 2025 Financial Highlights vs. Q2 2024 | Metric | Q2 2025 | Q2 2024 | Change | | :--- | :--- | :--- | :--- | | **Revenue** | $314.6M | $166.0M | +89.6% | | **Gross Profit** | $195.0M | $75.5M | +158.3% | | **Net Loss** | ($42.8M) | ($552.2M) | NM | | **Adjusted EBITDA** | ($5.6M) | ($31.2M) | +82.1% | | **Net Loss per Share** | ($0.25) | ($6.86) | +96.4% | | **Non-GAAP Net Loss per Share** | ($0.22) | ($0.63) | +65.1% | [Operational Highlights](index=1&type=section&id=Second%20Quarter%20and%20Recent%20Operational%20Highlights) Tempus strengthened its finances via a notes offering, expanded its AI clinical tools, advanced its monitoring capabilities, and grew its data assets - Completed an upsized offering of **$750 million 0.75% convertible senior notes** to enhance the balance sheet and reduce interest expenses[5](index=5&type=chunk)[6](index=6&type=chunk) - Expanded AI-powered clinical tools: **Tempus Next™ care pathway intelligence platform was extended into breast cancer**, and the **Tempus One™ generative AI assistant was integrated into leading EHR systems**[11](index=11&type=chunk) - Advanced monitoring capabilities by introducing **Tempus xM™**, a liquid biopsy assay for monitoring immunotherapy response, and expanded its collaboration with Personalis to include colorectal cancer for MRD testing[11](index=11&type=chunk) - Reached a new database milestone, now connected to over **40 million clinical patient records** and holding over **350 petabytes of connected clinical and molecular data**[11](index=11&type=chunk) [Financial Outlook and Guidance](index=3&type=section&id=Financial%20Outlook%20and%20Guidance) Tempus raised its full-year 2025 guidance, anticipating approximately $1.26 billion in revenue and positive Adjusted EBITDA of $5 million Full Year 2025 Guidance | Metric | Full Year 2025 Guidance | | :--- | :--- | | **Revenue** | ~$1.26 billion (~82% YoY growth) | | **Adjusted EBITDA** | $5 million (~$110M improvement vs. 2024) | [Consolidated Financial Statements](index=6&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20OPERATIONS%20AND%20COMPREHENSIVE%20LOSS) This section provides the unaudited condensed consolidated financial statements for the three and six months ended June 30, 2025, and 2024 [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=6&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20OPERATIONS%20AND%20COMPREHENSIVE%20LOSS) For Q2 2025, total net revenue increased significantly while the loss from operations and net loss per share both narrowed sharply YoY Statement of Operations Summary (Q2 2025 vs Q2 2024, in thousands) | Line Item | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | **Total net revenue** | $314,635 | $165,969 | | Genomics Revenue | $241,843 | $112,324 | | Data and services Revenue | $72,792 | $53,645 | | **Loss from operations** | $(61,774) | $(533,492) | | **Net Loss** | $(42,843) | $(552,212) | | **Net loss per share** | $(0.25) | $(6.86) | [Condensed Consolidated Balance Sheets](index=7&type=section&id=CONDENSED%20CONSOLIDATED%20BALANCE%20SHEETS) As of June 30, 2025, total assets, liabilities, and stockholders' equity all increased substantially compared to year-end 2024 Balance Sheet Summary (in thousands) | Category | June 30, 2025 | Dec 31, 2024 | | :--- | :--- | :--- | | **Total Current Assets** | $644,201 | $667,603 | | Cash and cash equivalents | $186,310 | $340,954 | | **Total Assets** | **$1,625,365** | **$926,116** | | **Total Current Liabilities** | $418,160 | $291,070 | | **Total Liabilities** | **$1,315,803** | **$869,777** | | **Total Stockholders' equity** | **$309,562** | **$56,339** | [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20CASH%20FLOWS) For the first six months of 2025, net cash used in operating activities improved significantly, while investing activities increased cash use Cash Flow Summary (Six Months Ended June 30, in thousands) | Activity | 2025 | 2024 | | :--- | :--- | :--- | | **Net cash used in operating activities** | $(61,460) | $(198,458) | | **Net cash (used in) provided by investing activities** | $(385,329) | $8,982 | | **Net cash provided by financing activities** | $293,042 | $502,631 | | **Net (decrease) increase in Cash** | $(153,784) | $313,065 | | **Cash, cash equivalents and restricted cash, end of period** | $188,051 | $479,672 | [Reconciliation of GAAP to Non-GAAP Financial Measures](index=11&type=section&id=RECONCILIATION%20OF%20GAAP%20TO%20NON-GAAP%20FINANCIAL%20MEASURES) This section details adjustments from GAAP to non-GAAP metrics, showing significant underlying performance improvement in key areas [Gross Profit & Gross Margin Reconciliation](index=11&type=section&id=Total%20Gross%20Profit%20%26%20Gross%20Margin) Non-GAAP gross profit and margin improved significantly year-over-year, driven by expansion in both Genomics and Data and Services segments Total Non-GAAP Gross Profit & Margin (Q2 2025 vs Q2 2024) | Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | **Gross Profit (GAAP)** | $195.0M | $75.5M | | **Non-GAAP Gross Profit** | $197.5M | $94.3M | | **Gross Margin (GAAP)** | 62.0% | 45.5% | | **Non-GAAP Gross Margin** | 62.8% | 56.8% | [Earnings per Share Reconciliation](index=12&type=section&id=Earnings%20per%20Share) After adjustments, the Non-GAAP net loss and net loss per share both showed marked improvement compared to the prior-year quarter Non-GAAP Net Loss per Share (Q2 2025 vs Q2 2024) | Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | **Net Loss (GAAP)** | ($42.8M) | ($552.2M) | | **Non-GAAP Net Loss** | ($37.3M) | ($51.9M) | | **Non-GAAP Net Loss per Share** | ($0.22) | ($0.63) | [Adjusted EBITDA Reconciliation](index=13&type=section&id=Adjusted%20EBITDA) Adjusted EBITDA improved by $25.6 million year-over-year, reflecting a substantially narrowed loss after key non-cash adjustments Adjusted EBITDA Reconciliation (Q2 2025 vs Q2 2024, in thousands) | Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | **Net loss** | $(42,843) | $(552,212) | | EBITDA | $5,887 | $(531,381) | | Stock-based compensation expense | $22,455 | $488,313 | | Fair value changes | $(37,546) | $4,870 | | **Adjusted EBITDA** | **$(5,580)** | **$(31,186)** | [Other Information](index=3&type=section&id=Other%20Information) This section provides supplementary details on conference calls, non-GAAP definitions, and forward-looking statements - Tempus defines and uses several **non-GAAP financial measures**, such as Non-GAAP gross profit, Non-GAAP operating expenses, and Adjusted EBITDA, to provide additional information on its financial and operational performance[14](index=14&type=chunk)[15](index=15&type=chunk)[16](index=16&type=chunk) - The report includes **forward-looking statements** regarding expected financial results and the benefits of its convertible notes, which are subject to risks and uncertainties[22](index=22&type=chunk)[23](index=23&type=chunk) - A conference call and webcast to discuss the results were scheduled for **August 8, 2025**[10](index=10&type=chunk)

Core Viewpoint - Tempus AI, Inc. is facing a class action lawsuit due to allegations of misleading statements and undisclosed material information during the Class Period from August 6, 2024, to May 27, 2025 [1][3]. Company Overview - Tempus AI is a technology company focused on advancing precision medicine through artificial intelligence, including generative AI [2]. Allegations of the Lawsuit - The lawsuit claims that Tempus AI inflated the value of certain contract agreements, many involving related parties, which included non-binding opt-ins or were self-funded [3]. - It is alleged that the company's joint venture with SoftBank Group Corporation risked credibility due to the appearance of "round-tripping" capital to artificially inflate revenue [3]. - The acquisition of Ambry Genetics Corporation is said to have operated under a business model reliant on aggressive and potentially unethical billing practices, exposing it to regulatory and financial risk [3]. - AstraZeneca PLC reportedly reduced its financial support to Tempus AI through a questionable "pass-through payment" structure involving a joint agreement with Pathos AI, Inc. [3]. - These issues are indicative of broader weaknesses in Tempus AI's core operations and long-term revenue outlook [3]. Impact on Stock Price - Following the publication of a research report by Spruce Point Capital Management, LLC on May 28, 2025, which raised serious concerns regarding Tempus AI's management and financial disclosures, the company's stock price fell by over 19% [4].

SAN DIEGO , Aug. 6, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, all dates inclusive (the "Class Period"), have until Tuesday, August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit.  Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI as well as certain of Tempus AI's ...

Core Viewpoint - The Tempus AI class action lawsuit alleges that the company and its executives made misleading statements and failed to disclose critical information that inflated the company's stock value during the specified class period [3][4]. Group 1: Allegations Against Tempus AI - The lawsuit claims that Tempus AI inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [3]. - It is alleged that the credibility of Tempus AI's joint venture with SoftBank Group Corporation was compromised, giving the appearance of "round-tripping" capital to create revenue [3]. - The business model of Ambry Genetics Corporation, acquired by Tempus AI, is said to be based on aggressive and potentially unethical billing practices, risking scrutiny and sustainability [3]. - AstraZeneca PLC reportedly reduced its financial commitments to Tempus AI through a questionable "pass-through payment" arrangement [3]. - These issues collectively indicate weaknesses in Tempus AI's core operations and revenue prospects [3]. Group 2: Impact of Allegations - Following a research report from Spruce Point Capital Management on May 28, 2025, which raised concerns about Tempus AI's management and financial reporting, the company's stock price fell by more than 19% [4]. Group 3: Class Action Process - Investors who purchased Tempus AI common stock during the class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [5]. - The lead plaintiff can select a law firm of their choice to litigate the case, and their ability to share in any potential recovery is not contingent upon serving as lead plaintiff [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [6].

Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. for allegedly misleading investors regarding its financial practices and operations, leading to significant stock price decline [1][4]. Group 1: Allegations and Issues - The complaint alleges that Tempus inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [3]. - Concerns were raised about the credibility of Tempus' joint venture with SoftBank, suggesting it appeared to involve "round-tripping" capital to create revenue [3]. - The business model of Tempus-acquired Ambry is criticized for aggressive and potentially unethical billing practices, risking scrutiny and sustainability [3]. - AstraZeneca reportedly reduced its financial commitments to Tempus through a questionable "pass-through payment" arrangement [3]. - The issues highlighted indicate weaknesses in Tempus' core operations and revenue prospects [3]. Group 2: Impact of Reports - On May 28, 2025, Spruce Point Capital Management issued a report raising multiple concerns about Tempus' management, operations, and financial reporting [4]. - The report pointed out that Tempus' actual AI capabilities may be overstated and that executives have ties to companies that have restated financial results [4]. - It also noted signs of aggressive accounting practices and issues with the AstraZeneca and Pathos AI deal that warrant further scrutiny [4]. - Following the release of this report, Tempus' stock price fell by $12.67 per share, or 19.23%, from $65.87 to $53.20 [5].

Core Viewpoint - Tempus AI, Inc. is facing a class action lawsuit due to allegations of misleading statements and undisclosed material information during the Class Period from August 6, 2024, to May 27, 2025 [1][3]. Group 1: Allegations Against Tempus AI - The lawsuit claims that Tempus AI inflated the value of certain contract agreements, many of which involved related parties and included non-binding opt-ins or were self-funded [3]. - It is alleged that the joint venture with SoftBank Group Corporation risked credibility due to the appearance of "round-tripping" capital to artificially inflate revenue [3]. - The acquisition of Ambry Genetics Corporation is said to have operated under a business model reliant on aggressive and potentially unethical billing practices, exposing it to regulatory and financial risks [3]. - AstraZeneca PLC reportedly reduced its financial support to Tempus AI through a questionable "pass-through payment" structure involving a joint agreement with Pathos AI, Inc. [3]. - These issues are indicative of broader weaknesses in Tempus AI's core operations and long-term revenue outlook [3]. Group 2: Impact of Research Report - On May 28, 2025, Spruce Point Capital Management, LLC published a research report that raised serious concerns regarding Tempus AI's management, operations, and financial disclosures [4]. - Following the release of this report, Tempus AI's stock price fell by over 19% [4].

Company Overview - Tempus AI has expanded its AI-enabled care pathway intelligence platform, Tempus Next, into breast cancer to address critical care gaps, initially designed for lung cancer [1][7] - The platform now focuses on five different biomarker testing gaps specific to breast cancer, aiming to help physicians deliver guideline-directed medical care [1][3] Market Insights - Breast cancer is one of the fastest-growing oncology segments globally, with a projected market value of $89.91 billion by 2034, growing at a CAGR of 9.9% from 2025 to 2034 [2] - The breast cancer diagnostics subsegment is expected to reach $8.47 billion by 2030, with a CAGR of 7.6% from 2025 to 2030 [2] Competitive Landscape - Hologic has expanded its Breast Health portfolio to cover the full breast cancer care continuum, including biopsy and surgery, and has started selling Endomag products in North America [4] - GE HealthCare launched the Invenia Automated Breast Ultrasound Premium, designed to improve early cancer detection through enhanced automation and AI [5] Financial Performance - Tempus AI shares have surged 70.8% year to date, outperforming the industry's 20% growth and the S&P 500 composite's 5.7% improvement [6] - The company currently trades at a forward 12-month Price-to-Sales (P/S) ratio of 6.96X, compared to the industry average of 5.91X [8] Earnings Estimates - In the past 30 days, Tempus AI's projected loss per share has improved by 2.8% for 2025 and 12% for 2026 [10]

Core Insights - Tempus AI, Inc. (TEM) is set to report its second-quarter 2025 results on August 8, with an adjusted loss of 24 cents in the last quarter, which was better than the Zacks Consensus Estimate of a loss of 27 cents per share [1] - The company is expected to see significant revenue growth, with the Zacks Consensus Estimate for Q2 revenues at $299.3 million, reflecting an 80.4% increase year-over-year [2] Financial Performance - The earnings estimate for the current quarter is a loss of 23 cents per share, which has narrowed by 4 cents over the past 90 days [2] - Tempus AI experienced a 34.5% gain in Q2 2025, outperforming the broader industry gain of 9.3% and the Medical sector's decline of 3.4% [3][4] Strategic Developments - A significant $200 million partnership with AstraZeneca and Pathos is expected to enhance long-term data monetization for Tempus AI, with revenues from this deal recognized over three years starting in Q2 [6][8] - The hereditary testing segment, bolstered by the acquisition of Ambry Genetics, is projected to continue its growth trend, with a 23% unit increase reported [9] Product Innovations - The company has expanded its diagnostics portfolio with the FDA clearance of its AI-powered ECG tool and the launch of a liquid biopsy assay, which are anticipated to contribute positively to Q2 revenues [10] - Tempus AI is advancing its digital health strategy by integrating its GenAI clinical assistant into EHR systems, which is expected to see strong customer adoption [11] Valuation and Market Position - TEM's stock is currently trading at a forward price-to-sales ratio of 6.86, which is higher than the industry average of 5.80 and other competitors like 10x Genomics and SOPHiA GENETICS [15] - Despite the strong growth potential in the AI market, the company's premium valuation and lack of near-term profitability may limit immediate gains [16][17]

Group 1 - The article suggests that there are opportunities in undervalued stocks that are mispriced by the market as of the end of July [1] - It encourages readers to consider joining a platform for insights on these investment opportunities [1] Group 2 - The article does not provide specific company or industry analysis, focusing instead on general investment advice [2][3][4]

SAN DIEGO, July 29, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the "Class Period"), have until Tuesday, August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI as well as certain of Tempus AI's top executi ...